E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy

Zhonglin Hao, Shuang Huang

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

E3 ubiquitin ligase Skp2 attaches ubiquitin to its target proteins and marks them for destruction by the 26S proteasome. This mechanism participates in a number of important cellular processes such as cell proliferation, DNA replication, V(D)J recombination, gene transcription, cellular metabolism and senescence. Skp2 is oncogenic. It is overexpressed in various solid tumors and hematological malignancies. Due to the antagonistic role Skp2 plays against p27, Skp2 overexpression is frequently associated with down-regulation of p27. Importantly, Skp2 overexpression in cancer cells is prognostic of cancer progression and overall survival. Recent studies have shown that Skp2 suppression might be an excellent strategy to inhibit tumorigenesis in tumors in which tumor suppressor genes such as VHL, RB or TP53 are mutated. In this review, we also summarize early efforts in the development of Skp2 inhibitors. The implications of continued, long-term Skp2 suppression are discussed.

Original languageEnglish (US)
Pages (from-to)474-490
Number of pages17
JournalFrontiers in Bioscience - Landmark
Volume20
Issue number3
DOIs
StatePublished - Jan 15 2015

Fingerprint

Ubiquitin-Protein Ligases
Tumors
Genes
Neoplasms
Cell proliferation
V(D)J Recombination
Transcription
Ubiquitin
Metabolism
Cell Aging
Hematologic Neoplasms
Therapeutics
Tumor Suppressor Genes
DNA Replication
Cells
Carcinogenesis
Down-Regulation
DNA
Cell Proliferation
Proteins

Keywords

  • Cancer therapy
  • E3 ubiquitin ligase
  • Inhibitor
  • Oncogenesis
  • Review
  • Skp2

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy. / Hao, Zhonglin; Huang, Shuang.

In: Frontiers in Bioscience - Landmark, Vol. 20, No. 3, 15.01.2015, p. 474-490.

Research output: Contribution to journalReview article

Hao, Zhonglin ; Huang, Shuang. / E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy. In: Frontiers in Bioscience - Landmark. 2015 ; Vol. 20, No. 3. pp. 474-490.
@article{5c597582a00b494b9055bb2ec4b5cc57,
title = "E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy",
abstract = "E3 ubiquitin ligase Skp2 attaches ubiquitin to its target proteins and marks them for destruction by the 26S proteasome. This mechanism participates in a number of important cellular processes such as cell proliferation, DNA replication, V(D)J recombination, gene transcription, cellular metabolism and senescence. Skp2 is oncogenic. It is overexpressed in various solid tumors and hematological malignancies. Due to the antagonistic role Skp2 plays against p27, Skp2 overexpression is frequently associated with down-regulation of p27. Importantly, Skp2 overexpression in cancer cells is prognostic of cancer progression and overall survival. Recent studies have shown that Skp2 suppression might be an excellent strategy to inhibit tumorigenesis in tumors in which tumor suppressor genes such as VHL, RB or TP53 are mutated. In this review, we also summarize early efforts in the development of Skp2 inhibitors. The implications of continued, long-term Skp2 suppression are discussed.",
keywords = "Cancer therapy, E3 ubiquitin ligase, Inhibitor, Oncogenesis, Review, Skp2",
author = "Zhonglin Hao and Shuang Huang",
year = "2015",
month = "1",
day = "15",
doi = "10.2741/4320",
language = "English (US)",
volume = "20",
pages = "474--490",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "3",

}

TY - JOUR

T1 - E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy

AU - Hao, Zhonglin

AU - Huang, Shuang

PY - 2015/1/15

Y1 - 2015/1/15

N2 - E3 ubiquitin ligase Skp2 attaches ubiquitin to its target proteins and marks them for destruction by the 26S proteasome. This mechanism participates in a number of important cellular processes such as cell proliferation, DNA replication, V(D)J recombination, gene transcription, cellular metabolism and senescence. Skp2 is oncogenic. It is overexpressed in various solid tumors and hematological malignancies. Due to the antagonistic role Skp2 plays against p27, Skp2 overexpression is frequently associated with down-regulation of p27. Importantly, Skp2 overexpression in cancer cells is prognostic of cancer progression and overall survival. Recent studies have shown that Skp2 suppression might be an excellent strategy to inhibit tumorigenesis in tumors in which tumor suppressor genes such as VHL, RB or TP53 are mutated. In this review, we also summarize early efforts in the development of Skp2 inhibitors. The implications of continued, long-term Skp2 suppression are discussed.

AB - E3 ubiquitin ligase Skp2 attaches ubiquitin to its target proteins and marks them for destruction by the 26S proteasome. This mechanism participates in a number of important cellular processes such as cell proliferation, DNA replication, V(D)J recombination, gene transcription, cellular metabolism and senescence. Skp2 is oncogenic. It is overexpressed in various solid tumors and hematological malignancies. Due to the antagonistic role Skp2 plays against p27, Skp2 overexpression is frequently associated with down-regulation of p27. Importantly, Skp2 overexpression in cancer cells is prognostic of cancer progression and overall survival. Recent studies have shown that Skp2 suppression might be an excellent strategy to inhibit tumorigenesis in tumors in which tumor suppressor genes such as VHL, RB or TP53 are mutated. In this review, we also summarize early efforts in the development of Skp2 inhibitors. The implications of continued, long-term Skp2 suppression are discussed.

KW - Cancer therapy

KW - E3 ubiquitin ligase

KW - Inhibitor

KW - Oncogenesis

KW - Review

KW - Skp2

UR - http://www.scopus.com/inward/record.url?scp=84918822949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918822949&partnerID=8YFLogxK

U2 - 10.2741/4320

DO - 10.2741/4320

M3 - Review article

C2 - 25553462

AN - SCOPUS:84918822949

VL - 20

SP - 474

EP - 490

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 3

ER -